Jennifer D. Zwicker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer D. Zwicker has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Wendy J. Ungar
The Hospital for Sick Children, Toronto, Canada
5 shared publications - Krystle Wittevrongel
School of Public Policy, University of Calgary, Downtown Campus (5th floor), 906 8th Ave SW, Calgary, AB T2P 1H, Canada
4 shared publications - Lynnette Nathalie Lyzwinski
Menrva Research Group, School of Mechatronics Systems Engineering and Engineering Science, Simon Fraser University, Vancouver, BC, Canada
4 shared publications - Sheila McDonald
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
4 shared publications - Suzanne Tough
Owerko Centre at Alberta Children's Hospital Research Institute, Calgary, Canada
4 shared publications - Xiao Yang Jia
The School of Public Policy, University of Calgary, Calgary, Canada
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Pharmacogenetics Governance for Youth Mental Health: A Scoping Review of Policy Across 13 Countries
Pharmacogenetics (PGx) testing could improve psychotropic prescribing for children and young people, yet youth‐specific policy guidance remains scarce. This review characterizes the international PGx policy landscape for youth mental health across 13 countries. From 940 records, 20 policy documents met inclusion criteria, yielding 190 passages for thematic analysis using the GE 3 LS framework. We found that 75% of policies primarily focused on guiding medication prescribing in adult populations, with limited consideration of youth populations; only one (5%) was designed specifically for youth. Three‐quarters of documents originated from professional organizations rather than governments, indicating a structural governance vacuum. An “inverted pyramid” of policy priorities was identified, with scientific (Genomics, 29.5%) and implementation (Social, 24.7%) considerations dominating over weak economic (7.9%) and legal (14.2%) foundations. Policy coverage primarily focused on medications used in adult populations (antidepressants 80%; cardiovascular 85%), with limited consideration of youth populations; anxiolytics, relevant in pediatric practice, were covered in only 5% of documents. Policymakers must prioritize enforceable, youth‐centered legislation to address these governance failures.
- 9 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessPharmacogenetics Governance for Youth Mental Health: A Scoping Review of Policy Across 13 Countries
Pharmacogenetics (PGx) testing could improve psychotropic prescribing for children and young people, yet youth‐specific policy guidance remains scarce. This review characterizes the international PGx policy landscape for youth mental health across 13 countries. From 940 records, 20 policy documents met inclusion criteria, yielding 190 passages for thematic analysis using the GE 3 LS framework. We found that 75% of policies primarily focused on guiding medication prescribing in adult populations, with limited consideration of youth populations; only one (5%) was designed specifically for youth. Three‐quarters of documents originated from professional organizations rather than governments, indicating a structural governance vacuum. An “inverted pyramid” of policy priorities was identified, with scientific (Genomics, 29.5%) and implementation (Social, 24.7%) considerations dominating over weak economic (7.9%) and legal (14.2%) foundations. Policy coverage primarily focused on medications used in adult populations (antidepressants 80%; cardiovascular 85%), with limited consideration of youth populations; anxiolytics, relevant in pediatric practice, were covered in only 5% of documents. Policymakers must prioritize enforceable, youth‐centered legislation to address these governance failures.
- Open Access
- 9 September 2026
- Published by Springer Nature in BMC Health Services Research
Public payer resource use, costs and parental well-being in children with emerging developmental disabilities
- 9 September 2026
- Published by Springer Nature in BMC Health Services Research
Open AccessPublic payer resource use, costs and parental well-being in children with emerging developmental disabilities
- Open Access
- 14 July 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (11) , 1309-1317
Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Practical Guidance
Neurodevelopmental disorders are lifelong conditions with onset in early childhood that impair cognitive, social, behavioural and physical functioning. Their consequences extend beyond healthcare, shaping education, social and community services, and family life. Economic evaluations can guide payers by quantifying the value for money of interventions, but standard methods require adaptation for this context. This paper offers practical guidance for pharmacoeconomic evaluations of interventions for children with neurodevelopmental disorders, synthesising methodological literature and applied experience to articulate core challenges, recommend solutions and highlight emerging opportunities. Evaluations must address five inter-related issues: defining and justifying an analytic perspective that captures multi-sectoral costs and benefits; identifying and valuing direct, indirect and intangible costs across health, education and social domains; selecting outcomes sensitive to changes in child functioning and health-related quality of life that can be economically valued; incorporating spillover effects for caregivers and families; and modelling long-term developmental trajectories amid data scarcity and uncertainty. We recommend adopting a societal perspective; applying comprehensive context-appropriate costing; combining generic and condition-specific outcome measures; explicitly including caregiver and family impacts; integrating equity analyses; and using long time horizons supported by robust modelling such as microsimulation or agent-based approaches. Promising directions include capability-based frameworks and digital biomarkers to enable real-world measurement of function and quality of life. Tailored pharmacoeconomic methods are essential for credible policy-relevant evaluations of neurodevelopmental disorder interventions. Transparent reporting and alignment with international standards will improve comparability, support uptake by decision makers, and promote equitable resource allocation for children and families affected by neurodevelopmental disorders.
- 14 July 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (11) , 1309-1317
Open AccessEconomic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Practical Guidance
Neurodevelopmental disorders are lifelong conditions with onset in early childhood that impair cognitive, social, behavioural and physical functioning. Their consequences extend beyond healthcare, shaping education, social and community services, and family life. Economic evaluations can guide payers by quantifying the value for money of interventions, but standard methods require adaptation for this context. This paper offers practical guidance for pharmacoeconomic evaluations of interventions for children with neurodevelopmental disorders, synthesising methodological literature and applied experience to articulate core challenges, recommend solutions and highlight emerging opportunities. Evaluations must address five inter-related issues: defining and justifying an analytic perspective that captures multi-sectoral costs and benefits; identifying and valuing direct, indirect and intangible costs across health, education and social domains; selecting outcomes sensitive to changes in child functioning and health-related quality of life that can be economically valued; incorporating spillover effects for caregivers and families; and modelling long-term developmental trajectories amid data scarcity and uncertainty. We recommend adopting a societal perspective; applying comprehensive context-appropriate costing; combining generic and condition-specific outcome measures; explicitly including caregiver and family impacts; integrating equity analyses; and using long time horizons supported by robust modelling such as microsimulation or agent-based approaches. Promising directions include capability-based frameworks and digital biomarkers to enable real-world measurement of function and quality of life. Tailored pharmacoeconomic methods are essential for credible policy-relevant evaluations of neurodevelopmental disorder interventions. Transparent reporting and alignment with international standards will improve comparability, support uptake by decision makers, and promote equitable resource allocation for children and families affected by neurodevelopmental disorders.
- Open Access
Resource Use and Costs of Nurse Navigator Support for Parents of High-Risk Infants After Discharge from a Neonatal Intensive Care Unit
Background: Infants discharged home from a neonatal intensive care unit (NICU) often have multiple ongoing medical needs. The Coached, Coordinated, Enhanced Neonatal Transition (CCENT) program provides nurse navigator-led support for caregivers of high-risk infants through their first year after transitioning from the NICU to home. The objective was to compare health care resource use and costs between CCENT and standard care control groups post-discharge. Methods: Resource use and costs were collected at 4 months and 12 months post-discharge from families enrolled in the CCENT randomized controlled trial across Canada. Infant healthcare utilization and parent mental health service use and costs were analyzed from public health care system and family payer perspectives and were compared statistically between groups and within groups over time. Results: A total of 97 and 105 infants were randomized to the intervention and control groups, respectively. Significant reductions in use of medications and equipment were observed over time in both groups while use of allied health professionals decreased and emergency department (ED) visits increased for CCENT. Annual total healthcare costs per child to the public payer were $4135 (95% CI $2825, $5709) for the CCENT group and $4578 (95% CI $2246, $8356) for controls. The cost of delivering CCENT was $669 per family (SD $362). The average annual out-of-pocket cost per family was $724 (95% CI $467, $1024) for CCENT and $728 (95% CI $479, $1007) for controls. Conclusions: This study indicates the importance of considering patterns of healthcare utilization, program costs and costs to families when implementing NICU to home care interventions. Excluding the cost of a nurse navigator, costs to the healthcare system were not increased in the intervention group. Such a program may help families access appropriate care.
Open AccessResource Use and Costs of Nurse Navigator Support for Parents of High-Risk Infants After Discharge from a Neonatal Intensive Care Unit
Background: Infants discharged home from a neonatal intensive care unit (NICU) often have multiple ongoing medical needs. The Coached, Coordinated, Enhanced Neonatal Transition (CCENT) program provides nurse navigator-led support for caregivers of high-risk infants through their first year after transitioning from the NICU to home. The objective was to compare health care resource use and costs between CCENT and standard care control groups post-discharge. Methods: Resource use and costs were collected at 4 months and 12 months post-discharge from families enrolled in the CCENT randomized controlled trial across Canada. Infant healthcare utilization and parent mental health service use and costs were analyzed from public health care system and family payer perspectives and were compared statistically between groups and within groups over time. Results: A total of 97 and 105 infants were randomized to the intervention and control groups, respectively. Significant reductions in use of medications and equipment were observed over time in both groups while use of allied health professionals decreased and emergency department (ED) visits increased for CCENT. Annual total healthcare costs per child to the public payer were $4135 (95% CI $2825, $5709) for the CCENT group and $4578 (95% CI $2246, $8356) for controls. The cost of delivering CCENT was $669 per family (SD $362). The average annual out-of-pocket cost per family was $724 (95% CI $467, $1024) for CCENT and $728 (95% CI $479, $1007) for controls. Conclusions: This study indicates the importance of considering patterns of healthcare utilization, program costs and costs to families when implementing NICU to home care interventions. Excluding the cost of a nurse navigator, costs to the healthcare system were not increased in the intervention group. Such a program may help families access appropriate care.
- Open Access
- 7 March 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Parent coaching program for children with emerging developmental disabilities while on a waitlist for services: cost analysis from a family payer perspective
Pre-school children with or at risk of developmental disabilities have diverse care needs in this critical period for neurodevelopment. Complexities in ser
- 7 March 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Open AccessParent coaching program for children with emerging developmental disabilities while on a waitlist for services: cost analysis from a family payer perspective
Pre-school children with or at risk of developmental disabilities have diverse care needs in this critical period for neurodevelopment. Complexities in ser
- Open Access
- 22 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 125
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial
Background: Treating depression and anxiety in adolescents can be challenging due to interindividual variability in medication response. With current trial-and-error prescribing practices, adolescents may undergo multiple medication changes over months or years before an effective and tolerated drug and dose are identified. Pharmacogenomic (PGx) testing can identify interindividual differences in drug metabolism, and evidence supporting PGx-guided prescribing in adults with mental disorders is growing. However, its impact on pediatric psychotropic prescribing remains underexplored. Methods: This is a protocol for a parallel-arm, multicentre, randomized controlled trial. Canadian adolescents aged 12–17 years who are initiating or switching a selective serotonin reuptake inhibitor (SSRI) for depression and/or an anxiety disorder under physician care are eligible. A total of 452 participants will be randomized 1:1 to PGx-guided SSRI prescribing (experimental) or SSRI prescribing based on current practice guidelines (control). Participants, caregivers, prescribing clinicians, outcome assessors, and investigators will be blinded to treatment allocation. Dual primary outcomes are symptom remission at 12 weeks, measured with the Quick Inventory of Depressive Symptomatology–Adolescent (QIDS-A17-SR) and the Screen for Child Anxiety Related Disorders (SCARED). Secondary outcomes, assessed at 4, 8, and 12 weeks, include participant- and physician-rated changes in depressive and anxiety symptoms, role functioning, health-related quality of life, health care utilization, cost-effectiveness, side-effect burden, medication burden, and adherence. Multiple testing will be addressed using the Hochberg method, and a parallel gated analysis will account for non-actionable genotypes. Secondary analysis will estimate minimal clinically important differences for symptom and role-functioning change with PGx-guided therapy. Discussion: At the time of writing, 36 participants have consented and been randomized to an intervention. This trial will evaluate whether PGx-guided prescribing improves symptom remission in adolescents treated with SSRIs. If efficacious, results should be interpreted with existing pediatric pharmacokinetic, observational, and adult trial data to inform PGx use in managing pediatric anxiety and depressive disorders.
- 22 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 125
Open AccessPharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial
Background: Treating depression and anxiety in adolescents can be challenging due to interindividual variability in medication response. With current trial-and-error prescribing practices, adolescents may undergo multiple medication changes over months or years before an effective and tolerated drug and dose are identified. Pharmacogenomic (PGx) testing can identify interindividual differences in drug metabolism, and evidence supporting PGx-guided prescribing in adults with mental disorders is growing. However, its impact on pediatric psychotropic prescribing remains underexplored. Methods: This is a protocol for a parallel-arm, multicentre, randomized controlled trial. Canadian adolescents aged 12–17 years who are initiating or switching a selective serotonin reuptake inhibitor (SSRI) for depression and/or an anxiety disorder under physician care are eligible. A total of 452 participants will be randomized 1:1 to PGx-guided SSRI prescribing (experimental) or SSRI prescribing based on current practice guidelines (control). Participants, caregivers, prescribing clinicians, outcome assessors, and investigators will be blinded to treatment allocation. Dual primary outcomes are symptom remission at 12 weeks, measured with the Quick Inventory of Depressive Symptomatology–Adolescent (QIDS-A17-SR) and the Screen for Child Anxiety Related Disorders (SCARED). Secondary outcomes, assessed at 4, 8, and 12 weeks, include participant- and physician-rated changes in depressive and anxiety symptoms, role functioning, health-related quality of life, health care utilization, cost-effectiveness, side-effect burden, medication burden, and adherence. Multiple testing will be addressed using the Hochberg method, and a parallel gated analysis will account for non-actionable genotypes. Secondary analysis will estimate minimal clinically important differences for symptom and role-functioning change with PGx-guided therapy. Discussion: At the time of writing, 36 participants have consented and been randomized to an intervention. This trial will evaluate whether PGx-guided prescribing improves symptom remission in adolescents treated with SSRIs. If efficacious, results should be interpreted with existing pediatric pharmacokinetic, observational, and adult trial data to inform PGx use in managing pediatric anxiety and depressive disorders.
- Open Access
- 29 December 2025
- Published by Wiley in Child: Care, Health and Development
- Vol. 52 (1) , e70213
Improving Equitable Access to Disability Services and Support for Children With Neurodevelopmental Disabilities: Service Provider and Decision‐Maker Perspectives
Background: Disparity in access to services for children with neurodevelopmental disabilities is a modifiable barrier to improving health, functional outcomes and social participation. Unfortunately, children and youth with neurodevelopmental disabilities face many barriers in accessing education and disability services and support. This study aimed to describe the perspectives of service providers and decision‐makers about disparities in access to disability services and support for children and youth with neurodevelopmental disabilities and their families. Methods: Utilizing a qualitative descriptive methodology informed by a pragmatic epistemological approach, we interviewed 16 individual service providers and decision‐makers from childhood education and disability services across ministries in British Columbia. Purposeful and maximum variation sampling was used to guide the selection of participants. An advisory council provided patient and family‐oriented perspectives and reviewed, piloted and refined the semi‐structured interview guide. Data was analysed with inductive thematic analysis. Results: System barriers and facilitators to accessing education and disability services and support were identified both through the navigation journey and across ministries. To address these barriers and leverage facilitators, policy and program design recommendations were identified, including an approach for framing policy as a ‘wider door’ and developing a holistic system that ‘works for everybody’. Conclusions: Systemic barriers and facilitators intertwine within the system before, during and after engagement with families and children. This creates a complex delivery environment, hindering the equitable provision of disability services and support. The findings provide a systemic and intersectoral overview of the interconnected challenges encountered while navigating the system, relevant to many jurisdictions.
- 29 December 2025
- Published by Wiley in Child: Care, Health and Development
- Vol. 52 (1) , e70213
Open AccessImproving Equitable Access to Disability Services and Support for Children With Neurodevelopmental Disabilities: Service Provider and Decision‐Maker Perspectives
Background: Disparity in access to services for children with neurodevelopmental disabilities is a modifiable barrier to improving health, functional outcomes and social participation. Unfortunately, children and youth with neurodevelopmental disabilities face many barriers in accessing education and disability services and support. This study aimed to describe the perspectives of service providers and decision‐makers about disparities in access to disability services and support for children and youth with neurodevelopmental disabilities and their families. Methods: Utilizing a qualitative descriptive methodology informed by a pragmatic epistemological approach, we interviewed 16 individual service providers and decision‐makers from childhood education and disability services across ministries in British Columbia. Purposeful and maximum variation sampling was used to guide the selection of participants. An advisory council provided patient and family‐oriented perspectives and reviewed, piloted and refined the semi‐structured interview guide. Data was analysed with inductive thematic analysis. Results: System barriers and facilitators to accessing education and disability services and support were identified both through the navigation journey and across ministries. To address these barriers and leverage facilitators, policy and program design recommendations were identified, including an approach for framing policy as a ‘wider door’ and developing a holistic system that ‘works for everybody’. Conclusions: Systemic barriers and facilitators intertwine within the system before, during and after engagement with families and children. This creates a complex delivery environment, hindering the equitable provision of disability services and support. The findings provide a systemic and intersectoral overview of the interconnected challenges encountered while navigating the system, relevant to many jurisdictions.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1612509
Service access for youth with neurodevelopmental disabilities transitioning to adulthood: service providers’ and decision-makers’ perspectives on barriers, facilitators and policy recommendations
Introduction: Youth with Neurodevelopmental Disabilities (NDD) who are transitioning to adulthood often struggle with accessing services. This limited access can result in poorer health, reduced ability to perform daily activities and engage in independent living and decreased levels of participation in society. Despite Canada’s commitment to the UN Convention on the Rights of Persons with Disabilities, British Columbia (BC) youth with NDD face additional barriers. Methods: This study investigated service providers’ and decision-makers’ perspectives on barriers, facilitators and policy recommendations for accessing BC’s health, education and disability services for youth with NDD. We conducted a qualitative descriptive study with 15 semi-structured interviews. We conducted inductive thematic coding to generate themes, which we then organized and interpreted using Bronfenbrenner’s ecological model. Results: Findings revealed that fragmented organizational structures, eligibility criteria, limited and unstable funding and enduring stigma impede service access, while coordinated inter-agency collaboration, clear transition planning and early, family-centered interventions may improve outcomes. Discussion: Targeted policy reforms across multiple ecological levels are essential to reduce inequities in service access and strengthen the continuum of support for youth with NDD as they transition to adulthood.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1612509
Open AccessService access for youth with neurodevelopmental disabilities transitioning to adulthood: service providers’ and decision-makers’ perspectives on barriers, facilitators and policy recommendations
Introduction: Youth with Neurodevelopmental Disabilities (NDD) who are transitioning to adulthood often struggle with accessing services. This limited access can result in poorer health, reduced ability to perform daily activities and engage in independent living and decreased levels of participation in society. Despite Canada’s commitment to the UN Convention on the Rights of Persons with Disabilities, British Columbia (BC) youth with NDD face additional barriers. Methods: This study investigated service providers’ and decision-makers’ perspectives on barriers, facilitators and policy recommendations for accessing BC’s health, education and disability services for youth with NDD. We conducted a qualitative descriptive study with 15 semi-structured interviews. We conducted inductive thematic coding to generate themes, which we then organized and interpreted using Bronfenbrenner’s ecological model. Results: Findings revealed that fragmented organizational structures, eligibility criteria, limited and unstable funding and enduring stigma impede service access, while coordinated inter-agency collaboration, clear transition planning and early, family-centered interventions may improve outcomes. Discussion: Targeted policy reforms across multiple ecological levels are essential to reduce inequities in service access and strengthen the continuum of support for youth with NDD as they transition to adulthood.
- Open Access
- 29 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312195
Clinical and socioeconomic predictors of hospital use and emergency department visits among children with medical complexity: A machine learning approach using administrative data
Objectives: The primary objective of this study was to identify clinical and socioeconomic predictors of hospital and ED use among children with medical complexity within 1 and 5 years of an initial discharge between 2010 and 2013. A secondary objective was to estimate marginal associations between important predictors and resource use. Methods: This retrospective, population-cohort study of children with medical complexity in Alberta linked administrative health data with Canadian census data and used tree-based, gradient-boosted regression models to identify clinical and socioeconomic predictors of resource use. Separate analyses of cumulative numbers of hospital days and ED visits modeled the probability of any resource use and, when present, the amount of resource use. We used relative importance in each analysis to identify important predictors. Results: The analytic sample included 11 105 children with medical complexity. The best short- and long-term predictors of having a hospital stay and number of hospital days were initial length of stay and clinical classification. Initial length of stay, residence rurality, and other socioeconomic factors were top predictors of short-term ED use. The top predictors of ED use in the long term were almost exclusively socioeconomic, with rurality a top predictor of number of ED visits. Estimates of marginal associations between initial length of stay and resource use showed that average number of hospital days increases as initial length of stay increases up to approximately 90 days. Children with medical complexity living in rural areas had more ED visits on average than those living in urban or metropolitan areas. Conclusions: Clinical factors are generally better predictors of hospital use whereas socioeconomic factors are more predictive of ED use among children with medical complexity in Alberta. The results confirm existing literature on the importance of socioeconomic factors with respect to health care use by children with medical complexity.
- 29 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0312195
Open AccessClinical and socioeconomic predictors of hospital use and emergency department visits among children with medical complexity: A machine learning approach using administrative data
Objectives: The primary objective of this study was to identify clinical and socioeconomic predictors of hospital and ED use among children with medical complexity within 1 and 5 years of an initial discharge between 2010 and 2013. A secondary objective was to estimate marginal associations between important predictors and resource use. Methods: This retrospective, population-cohort study of children with medical complexity in Alberta linked administrative health data with Canadian census data and used tree-based, gradient-boosted regression models to identify clinical and socioeconomic predictors of resource use. Separate analyses of cumulative numbers of hospital days and ED visits modeled the probability of any resource use and, when present, the amount of resource use. We used relative importance in each analysis to identify important predictors. Results: The analytic sample included 11 105 children with medical complexity. The best short- and long-term predictors of having a hospital stay and number of hospital days were initial length of stay and clinical classification. Initial length of stay, residence rurality, and other socioeconomic factors were top predictors of short-term ED use. The top predictors of ED use in the long term were almost exclusively socioeconomic, with rurality a top predictor of number of ED visits. Estimates of marginal associations between initial length of stay and resource use showed that average number of hospital days increases as initial length of stay increases up to approximately 90 days. Children with medical complexity living in rural areas had more ED visits on average than those living in urban or metropolitan areas. Conclusions: Clinical factors are generally better predictors of hospital use whereas socioeconomic factors are more predictive of ED use among children with medical complexity in Alberta. The results confirm existing literature on the importance of socioeconomic factors with respect to health care use by children with medical complexity.